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Abstract
Background: Due to methodological shortcomings the available post-registration data on the adverse events (AEs)
occurring in interferon beta-1a (INFb-1a)-treated patients fail to adequately validate phase III data and only partially inform
on safety in daily practice. We assessed AEs in relapsing remitting multiple sclerosis (RRMS) patients treated with
intramuscular (IM) INFb-1a in daily practice using data quality assurance measures similar to those in phase III trials.
Methods: A prospective, International Conference on Harmonization (ICH) - Good Clinical Practice (GCP)-based, clinical
research organization (CRO)-supported study in 36 practices in the Netherlands, Belgium, the United Kingdom and
Luxembourg. During 24 months after start of IM INFb-1a treatment 275 RRMS patients were assessed for AEs’ severity (mild,
moderate, severe) and relationship to treatment (not, unlikely, likely, definite). Data were compared with those reported in
the pivotal phase III trial.
Findings: 75.3% of the patients experienced one or more AEs that were likely or definitely related to INFb-1a. Of all AEs
40.5% were likely or definitely treatment-related; 68.5% of these were mild, and 3% severe. 6.6% of the patients
discontinued treatment because of an AE. Compared to the pivotal phase III trial, we found statistically significantly lower
incidences for most of the common AEs: headache, muscle ache, fatigue, fever, chills, nausea. One patient died following
two cerebral vascular events in study month 22, both AEs were assessed as not related to INFb-1a.
Conclusion: Three out of four RRMS patients treated with IM INFb-1a in daily practice experience treatment-related AEs,
most of these being mild. Our data externally validate the favorable phase III safety profile of IM INFb-1a and suggest that
the real-life incidence of treatment-related AEs is less than reported in the pivotal phase III trial. Larger studies are needed to
detect rare, potentially hazardous AEs of IM INFb-1a.
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Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinat-
ing disorder of the central nervous system (CNS) characterized by
increasing disability [1]. Approximately 85% of the patients are
initially diagnosed with relapsing-remitting MS (RRMS), which is
characterized by partial or complete recovery after relapses [1,2].
Interferon beta-1a (INFb-1a), administered intramuscular (IM)
once weekly in a dose of 30 microgram (AvonexH), is a first-line
disease modifying drug (DMD) for the treatment of patients with
RRMS. A phase III randomized placebo-controlled trial demon-
strated the efficacy of IM INFb-1a in reducing relapses and
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(AEs) [3]. Symptoms reported more frequently by IM INFb-1a-
treated than by placebo-treated patients were headache, flu-like
symptoms, muscle aches, nausea, fever, asthenia, chills and
diarrhoea [3].
Phase III trials of two years duration in limited numbers of
patients cannot fully inform on AEs. After registration of a drug
phase IV studies are needed for external validation and for the
detection of rare and long-term AEs. Yet, most post-registration
studies on IM INFb-1a only partially addressed safety aspects [4–
9]. Moreover, studies were often single-centred, restricted to
academic settings, performed in one region or country, or
retrospective [4–12]. Some studies also included patients treated
with subcutaneous INFb-1a or INFb-1b, with numbers too small
to enable informative subgroup analysis [13,14]. As a result, the
available post-registration data on the safety of IM INFb-1a fail to
adequately confirm phase III data and only partially inform on
AEs in daily practice.
Phase III trials are strictly conducted according to the
International Conference of Harmonization (ICH) guidelines on
Good Clinical Practice (GCP) and involve clinical research
organizations (CROs) [15]. The use of standardised and detailed
clinical research files (CRFs) and standard operating procedures
(SOPs), and regular monitoring contribute to consistency,
completeness, and overall quality of AE data. In contrast, phase
IV studies are not likely to engage CROs, use detailed CRFs or
explicitly monitor the application of ICH-GCP guidelines. Due to
these methodological differences the assessments of AEs in phase
IV studies may lack the quality that is needed for adequate
validation of phase III data, and are most likely incomplete. At the
same time there is an obvious need of detailed and quantitative
information on AEs in real life, as patients and doctors base their
choices between treatment options on weighing benefits against
risks [16].
To our knowledge, prospective, ICH-GCP-based, CRO-
supported studies on AEs in patients treated with IM INFb-1a
in daily practice have not been performed. The FLAIR
(Functional composite and quality of Life in Avonex-treated
Relapsing multiple sclerosis patients) study was designed to
prospectively evaluate health-related quality of life (HRQoL),
disability and AEs in RRMS patients treated with IM INFb-1a in
real life settings. Two-hundred-eighty-four patients were included
in 36 hospitals and specialised MS centres in the Netherlands,
Belgium, the United Kingdom and Luxemburg. HRQoL and
disability in these patients have been reported previously [17].
Here we present the AE results of the study.
Results
Patients
A total of 284 patients were included. In the Netherlands 151
patients (17 sites), Belgium 117 patients (16 sites), the U.K. 15
patients (two sites), and Luxemburg (one patient, one site). Eighty-
nine patients were male (31%), 195 female (69%). Mean age was
38.6 years (SD 10.1), mean disease duration 6.6 years (Standard
Deviation [SD] 6.6), mean pre-study annualized relapse rate 2.2
(SD 1.0), and mean baseline EDSS score 2.4 (SD 1.2). Two-
hundred-and-four patients (71.8%) completed the study, whereas
80 (28.2%) discontinued prematurely. Reasons for discontinuation
were: AE(s) in 22 (7.7%), non-compliance in 4 (1.4%), withdrawal
of consent in 28 (9.9%), lost to follow-up in 9 (3.2%), relapse in 9
(3.2%), investigator’s decision in 1 (0.4%), and other reason in 7
patients (2.5%). Mean time to discontinuation was 329.7 (SD
224.7) days. A total of 275 patients (96.8%) were included in the
safety analysis set.
Adverse events overall
A summary of AEs is shown in Table 1. Two-hundred-forty-five
(89%) patients experienced one or more AEs, and 207 patients
(75.3%) experienced one or more AEs that were classified as
definitively or likely related to INFb-1a. More than 40% of all AEs
were considered definitively or likely related to INFb-1a. AEs likely
related to INFb-1a were reported by 125 patients (45.5%), and
definitely related AEs by 120 (43.6%).
The majority of all AEs were mild (64.6%), 30.3% was
moderate and only 4.2% severe. Table 2 shows the numbers
and percentages of mild, moderate, and severe AEs according to
relationship to INFb-1a treatment. The majority of likely or
definitely related AEs were mild, and related AEs that qualified as
severe were rare.
In 22 patients (8.0%) AEs led to withdrawal from the study, in
18 (6.6%) the AE was considered related to INFb-1a.
Adverse events by body system
Table 3 presents the most often reported related AEs, occurring
in at least 4% of the patients. The body system most often affected
by related AEs was ‘body as a whole’. The most often reported
related AEs were, by decreasing frequency, flu-like symptoms,
headache, muscle pain, injection site pain, fever, fatigue, and
depression.
Table 1. Overview of adverse events in 275 patients from the
safety analysis set.
Patients Events
N%n%
Any AE* All 245 89.1 967 100.0
Not related{ 193 70.2 579 59.9
Related{ 207 75.3 388 40.1
Non-serious 241 87.6 865 89.5
Serious 53 19.3 97 10.0
Deaths 1 0.4 2# 0.2
According to severity* Missing 5 1.8 8 0.8
Mild 208 75.6 625 64.6
Moderate 126 45.8 293 30.3
Severe 31 11.3 41 4.2
According to
relationship*
Missing 3 1.1 5 0.5
No 161 58.5 446 46.1
Unlikely 71 25.8 128 13.2
Likely 125 45.5 210 21.7
Definite 120 43.6 178 18.4
AEs leading to
withdrawal
All 22 8.0 38 3.9
No or unlikely related 6 2.2 9 0.9
Likely or definite related 18 6.5 29 3.0
N, number of patients; n, number of AEs; AE, adverse event;
*, patients could appear in more than one category;
{, not related, unlikely related or assessment missing;
{, likely related or definitely related;
#, two AEs in one patient were reported as leading to death.
doi:10.1371/journal.pone.0026568.t001
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A total of 97 SAEs were experienced by 53 patients (19.2%) and
pertained mostly to the nervous system. SAEs occurring in more
than one patient are presented in Table 4. The most often
reported SAE was ‘MS aggravation’. No other SAE was reported
in more than three patients (,1%). Five patients (1.8%) reported a
total of seven SAEs considered as likely related to INFb-1a:
depression, suicide attempt (two patients), MS aggravation (two
patients), gait disturbance and dystonia. Three SAEs - both suicide
attempts and one depression – resulted in discontinuation of INFb-
1a. No SAEs were classified as definitely related to INFb-1a. One
female patient, aged 58 years at baseline, died following a cerebral
vascular attack on study day 650 and a cerebral venous thrombosis
(sinus thrombosis) on study day 652. Both AEs were assessed as not
related to INFb-1a.
Discontinuation due to adverse events
A total of 38 AEs in 22 patients led to treatment discontinu-
ation. Twenty-nine AEs leading to discontinuation were assessed
as likely or definitively related to INFb-1a. The most common of
these were ‘flu-like symptoms’ (eight events), ‘depression’ and
‘headache’ (three events each). Three likely related AEs leading to
withdrawal were SAEs (two suicide attempts and one depression).
AEs leading to discontinuation in more than one patient are given
in Table 5, the most often reported AEs being ‘flu-like symptoms’
and ‘MS aggravation’.
Discussion
Clinicians and patients need detailed and quantified informa-
tion on incidence and severity of AEs as observed in real life [18].
In phase III trials selected patients are treated in settings not
representative of daily practice, and for these data to be clinically
useful they must be externally validated [19]. In spite of IM INFb-
1a being registered for RRMS in Europe in 1998, post-registration
data that adequately validate the safety profile reported in the
pivotal phase III trial are fragmentary.
With application of data quality assurance measures similar to
those in phase III trials, we assessed AEs in real life settings
representative of daily MS care in different countries. Over a 2
year period 75.3% of the patients had one or more (mean 1.8) AEs
that were likely or definitely related to INFb-1a, which makes that
40.1% of all health changes were considered treatment-related.
Most of the related AEs were mild, severe ones were infrequent,
and only rarely (3.0%) did related AEs result in treatment
Table 2. Overview of numbers and percentages of mild,
moderate, and severe adverse events according to
relationship to INFb-1a treatment.
Mild Moderate Severe Total
Not related 298 124 22 444
(31.1%) (12.9%) (2.3%) (46.4%)
Unlikely related 59 59 7 125
(6.2%) (6.2%) (0.7%) (13.1%)
Likely related 152 55 4 211
(15.9%) (5.7%) (0.4%) (22.0%)
Definitely related 114 56 8 178
(11.9%) (5.9%) (0.8%) (18.6%)
Total 623 294 41 958
(65.0%) (30.7%) (4.3%) (100%)
doi:10.1371/journal.pone.0026568.t002
Table 3. Most common likely or definitely INFb-1a-related
adverse events by body system in 275 patients.
Body system*{ Patients Events
N%n%
Body as a whole 197 71.6 277 71.4
Chills 8 2.9 8 2.1
Fatigue 11 4.0 11 2.8
Fever 11 4.0 14 3.6
Flu-like symptoms 144 52.4 150 38.7
Headache 36 13.1 37 9.5
Injection site pain 18 6.5 19 4.9
Malaise 5 1.8 6 1.5
Pain 4 1.5 4 1.0
Digestive system 10 3.6 11 2.8
Nausea 5 1.8 5 1.3
Musculoskeletal system 23 8.4 28 7.2
Muscle ache 20 7.3 23 5.9
Nervous system 40 14.5 45 11.6
Depression 11 4.0 11 2.8
MS aggravation 4 1.5 4 1.0
Sleep disturbance 5 1.8 5 1.3
Skin and appendages 10 3.6 10 2.6
N, number of patients; n, number of events;
*, in at least 4 patients; totalling 371 (95.6%);
{, patients could have events in more than one category.
doi:10.1371/journal.pone.0026568.t003
Table 4. Serious adverse events occurring in more than one
patient by body system in 275 patients.
Body system Patients Events
N% n
Body as a whole 6 2.2 8
Injury 2 0.7 2
Suicide attempt 2 0.7 2
Cardiovascular system 2 0.7 2
Digestive system 4 1.5 5
Colitis 2 0.7 2
Nervous system 41 14.9 68
Depression 2 0.7 2
Gait disturbance 2 0.7 2
MS aggravation 35 12.7 47
Paresthesia 3 1.1 3
Walking difficulty 3 1.1 3
Special senses 4 1.5 4
Optic neuritis 2 0.7 2
Urogenital system 4 1.5 5
N, number of patients; n, number of events; %, percentage based on N=275.
doi:10.1371/journal.pone.0026568.t004
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IM INFb-1a treatment was associated with an increase in mean
HRQoL. Although three-quarters of the patients reported mild
AEs, moderate ones were seen in less than half, and severe AEs
only in one in nine patients. It may be hypothesized that overall in
the study group AEs had no major impact on wellbeing and that
any impact was outweighed by perceived benefits e.g. a decrease in
relapses.
The demographic and neurological characteristics of the
patients in the present study were similar to those of the INFb-
1a-treated group in the pivotal phase III trial (mean age 36.7 [SD
7.2] years, mean disease duration 6.6 [SD 5.8] years, mean
baseline EDSS score 2.4 [SD 0.8]) [3]. This may relate to the fact
that in the countries where we performed our study the registered
indication of IM INFb-1a and the criteria for reimbursement are
actually based on the phase III inclusion criteria. Overall, the most
frequently occurring AEs in our patients were similar to those
reported by Jacobs et al. [3]. Interestingly, however, for the
majority of these AEs the incidences we observed were
significantly lower: headache (19.3% vs. 67%), muscle ache
(15.6% vs. 34%), fatigue (12.7% vs. 21%), fever (5.1% vs. 23%),
nausea (4.7% vs. 31%), and chills (2.9% vs. 21%); the differences
in injection site reactions and depression could not be calculated,
as the paper by Jacobs et al. only reported the ranges (Table 6).
Thus, apart from flu-like symptoms, the various major AEs were
3.6 to 17.2 times less frequent in our patient population than in the
INFb-1a-treated phase III group. This discrepancy may relate to
the fact that the setting of a registration study facilitates AE
reporting, as doctors and nurses have ample time to communicate
with patients, whereas in daily practice there may be a bias
towards reporting of those AEs that are thought of as clinically
relevant. Moreover, patients participating in phase III studies
might be more motivated to report any change in health status.
Differences in patients’ motivation and communication with
caregivers may also explain why 6.6% of our patients discontinued
treatment due to INFb-1a-related AEs, in contrast with only one
INF-b-1a-treated patient (,1%) in the phase III study who
discontinued treatment because of an AE [3].
It is unlikely that the symptomatic treatment of AEs in our study
explains the lower incidences. We advised patients acetaminophen
625–1000 mg/day Q 4 hours and if necessary a NSAID for
treatment of influenza-like symptoms, whereas neurologists were
advised to treat fatigue with amantadine and spasticity with
baclophen, when deemed necessary.
Likewise, during the pivotal phase III study acetaminophen,
650 mg, was given prior to and for 24 hours after each injection,
and patients received appropriate medical care, including
antidepressants and antispastic drugs [3].
To our knowledge two studies specifically investigated IM
INFb-1a-related AEs in daily practice [10,11]. Both were
performed in academic hospitals and included 27 and 96 patients,
respectively. Reports did not inform on measures assuring data
quality. As the terms to denominate AEs and ways of presenting
data vary between studies comparisons are difficult. Fernandez et
al. reported on safety in RRMS patients, treated with IM INFb-1a
in three centers over a period of 2 years (Table 7). Incidences of
asthenia (45.1%) and fever (42.9%) were remarkably higher than
found in the dose-comparing phase IIIb by Clanet et al. and in our
study [20]. The incidence of depression was in the same range as
in our patients (10%), but in only 4% we considered depression
treatment-related; and in the phase IIIb study depression was
reported by 35% of the patients in the 30 mg group [20] (Table 7).
In fact, it may be difficult for patients and doctors to differentiate
symptoms relating to INFb-1a from similar MS symptoms
(asthenia, fatigue, depression, muscle aches) or from health
changes that are frequent in the general population (headache).
In long duration trials, most patients will report at least one AE
and making sense of common, reversible and minor AEs is
difficult. Assessment of any relationship between AEs and INFb-1a
also depends on the experience doctors and patients have with
both MS and INFb-1a. Cultural factors may also be at play. Yet,
for four of the five most common AEs the incidence found in our
study corresponded with the estimates given in the SPC and
package leaflet texts.
Table 6. Adverse events reported more frequently by INFb-
1a-treated than placebo-treated patients in the pivotal IM
INFb-1a phase III study (Jacobs et al. 1996) compared to
frequency of similar adverse events in the present study.
Jacobs et al.
Phase III FLAIR study Phase IV
All AEs Related AEs
N% N% N%
Chills 33 21 8 2.9** 8 2.9**
Fatigue{ 33 21 35 12.7* 16 5.8**
Fever 37 23 14 5.1** 11 4.0**
Flu-like symptoms 96 61 145 52.7 144 52.4
Headache 106 67 53 19.3** 36 13.1**
Nausea 49 31 13 4.7** 5 1.8**
Muscle ache{ 53 34 43 15.6** 20 7.2**
Pain 14 5.1 4 1.5
Injections site reactions# 10–15 18 6.5 18 6.5
Depression 10–15 28 10.2 11 4.0
N, number of patients;
{, asthenia in Jacobs et al.; fatigue and malaise in INFb-1a-related AEs in FLAIR
patients;
{, including muscle pain and myalgia in FLAIR patients;
#, injection site pain in FLAIR patients;
*, P,0.05;
**, P,0.0001. Differences in frequencies of injection site reactions and
depression were not statistically tested.
doi:10.1371/journal.pone.0026568.t006
Table 5. Adverse events leading to withdrawal in more than
one patient presented by body system in 275 patients.
Body system Patients Events
N%n
Body as a whole 14 5.1 20
Fatigue 2 0.7 2
Flu-like symptoms 9 3.3 9
Headache 3 1.1 3
Suicide attempt 2 0.7 2
Musculoskeletal system 2 0.7 2
Muscle pain 2 0.7 2
Nervous system 10 3.6 13
Depression 3 1.1 3
MS aggravation 4 1.5 4
N, number of patients; n, number of events.
doi:10.1371/journal.pone.0026568.t005
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12 patients (6.2%) in the INFb-1a-treated phase III study group
[3], whereas in the present study 1.8% of the patients reported
seven treatment-related SAEs: suicide attempt, depression and
worsening of neurological symptoms; of which two suicide
attempts and one depression resulted in discontinuation of
INFb-1a. A transient increase in spasticity following dosing with
INFb has been reported in MS patients [21,22]. A temporary
worsening of MS symptoms may also relate to INFb-1a-induced
fever. The absence of treatment-related SAEs in the pivotal phase
III trial may reflect a more restrictive patient screening procedure.
One of the patients died from a cerebral vascular attack and a
sinus thrombosis 21 months after start of INFb-1a, both AEs were
considered not treatment-related. Jacobs et al. reported that one
INFb-1a recipient died from pulmonary embolism and cardiac
arrhythmia designated as unrelated to the study drug [3]. These
observations may justify the question whether vascular events are a
rare side effect of INFb. On the other hand, factors like steroid use,
decreased mobility or associated medical conditions may also
increase the risk of vascular events in RRMS patients. Stroke after
initiation of INFb has been reported in a patient with RR white
matter disease, who turned out to have a primary angiitis of the
CNS [23]. Only prospectively acquired data in large patient
groups can answer this question.
This study has several limitations. Its size and duration preclude
detection of rare AEs or AEs that develop in the long term. As we
performed no laboratory assessments, subclinical changes have
gone undetected, although from a clinical point of view these
changes may be thought of as of minor importance. We also did
not differentiate between AEs occurring in the 1
st and the 2
nd year
of treatment. Incidences of AEs may change during a study [24],
and it has been known that INFb-related AEs typically start in the
first weeks and mostly subside within 3 to 6 months. In a 12-month
study in 27 RRMS patients who had started treatment with IM
IFNb-1a, the percentage of patients with AEs remained constant,
but the mean number of AEs increased significantly from the 6th
to the 12th month with significant changes over time for almost all
AEs [10].
In conclusion, when using phase III performance standards we
observed that 75.3% of RRMS patients who were treated for up to
2 years with IM INFb-1a in daily practice experienced one or
more (mean 1.8) treatment-related AEs. Most of these AEs were
mild, severe ones were rare, and 6.6% of the patients discontinued
INFb-1a because of a related AE. For the majority of the most
common treatment-related AEs the incidences were in accordance
with the SPC text. However, when compared to the pivotal phase
III trial we observed significantly lower incidences for most of the
treatment-related AEs [3].
Methods
Ethics statement
The decision to start IM INFb-1a was preceded by and
independent from the decision to inform patients about the study.
Written informed consent was obtained prior to any study-related
procedure. The study was conducted in accordance with the
Declaration of Helsinki (South Africa 1996), the ICH-GCP
guidelines, and in compliance with national drug laws [15,25].
The protocol was submitted to the Independent Review Board
(IRB), an approved ethical committee residing in Amsterdam, the
Netherlands. The IRB concluded that, because of the observational
design of the study, a review by an ethical committee was not
required, as the study did not qualify for being tested according to
the Dutch Medical Research Involving Human Subjects Act of
1999 [25]. Subsequently the ethical committees at all institutions
and hospitals where participants were recruited were informed by
the local investigators about the IRB’s judgment and the study
protocol was not reviewed by the local ethical committees.
Study design and administrative procedures
An investigator-initiated (PJJ), prospective, multi-centre, inter-
national, observational study, involving 46 neurologists in 36
practices in the Netherlands, Belgium, the United Kingdom and
Luxembourg. Twenty-two practices were in general hospitals, 10
in university hospitals and 4 in independent MS clinics. Study
duration was 24 months.
ClinicalTrials.gov identifier NCT00534261. The CRO Kendle
International was responsible for project management, monitor-
ing, data management and statistical analysis. A steering
committee provided scientific and medical direction and oversaw
the administrative progress. A patient was considered to be
enrolled once a baseline evaluation had been completed. Subjects
that withdrew before completion were followed-up, within 2 weeks
after discontinuation, as per month 24 and were not replaced. The
first patient entered the study on 4 November 1999 and the last
patient completed the study 11 February 2004.
Table 7. Incidences of most common adverse events as reported in the pivotal phase III study (Jacobs et a. 1996), the dose-
comparing phase IIIb study (Clanet et al. 2002), an observational phase IV study (Fernandez et al. 2003), the SPC text, and as found
in the present study.
Jacobs et al. Clanet et al. Fernandez et al. SPC text FLAIR study
All AEs Related AEs
Year 1996 2002 2003
Phase III IIIb IV IV IV
N 193 402 96 284 284
Headache 67% 28% ,10% .10% 19% 13%
Flu-like syndrome 61% 85% 45% .10% 53% 52%
Fever 23% 43% .10% 5% 4%
Asthenia/fatigue 21% .45% ,10% 13% 6%
Depression n.m.f. 35% 10% ,10% 10% 4%
SPC, Summary of Product Characteristics; n.m.f., not more frequent than in placebo-treated patients (Jacobs et al. 1996).
doi:10.1371/journal.pone.0026568.t007
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Commercially available drug was dispensed by the pharmacist as
per regular care and reconstituted and administered once a week
IM according to product instructions. Patients were instructed
how to inject and were offered a service provided by trained
registered nurses. The nurses visited patients at home and trained
them or their care-partners on how to administer.
Three protocol amendments were implemented after the
protocol was finalized on May 1999. The information in this
paper reflects the situation after Amendment 3. Changes regarding
safety were: No laboratory parameters were to be determined or
analyzed for this study (Amendment 1, dated 28 July 1999), and
serious adverse events (SAEs) monitoring and reporting were
specified (Amendment 2, dated 10 March 2000).
Eligibility criteria
Inclusion criteria were: 1) RRMS, 2) age between 18 and 70
years, inclusive, 3) two relapses in the last 24 months, 4) disease
duration of at least 12 months, 5) expanded disability status scale
(EDSS) score of 5.5 or less, 6) naı ¨ve with respect to INFb
treatment. Criteria 1 to 5 were according to the Summary of
Product Characteristics (SPC) and reimbursement policies.
Exclusion criteria were: 1) history of any significant cardiac,
hepatic, pulmonary or renal disease; immune deficiency; or other
medical conditions that would preclude therapy with INFb, 2)
history of severe allergic or anaphylactic reactions or history of
hypersensitivity to human albumin, 3) history of seizures within the
previous 3 months, 4) history of intolerance to INFs, 5) female
patients who were pregnant or breast feeding, 6) for female
subjects, unwillingness to practice effective contraception, as
defined by the investigator, unless postmenopausal or surgically
sterile; women considering becoming pregnant during the study
period of 24 months were to be excluded, 7) previous participation
in this study, 8) history of intolerance to acetaminophen
(paracetamol), naproxen or other non-steroidal anti-inflammatory
drugs (NSAIDs), that would preclude use of at least one of these
drugs. Criteria 1 to 6 were according to the SPC text.
Adverse events assessment and management
AEs were defined as any sign or medical diagnosis noted by
medical personnel or symptom reported by the patient, regardless
of relationship to treatment, that: 1) started any time after start of
treatment, whereby signs, symptoms and diagnoses occurring prior
to the first dose of INFb-1a were not considered to be AEs if they
did not increase in severity; or 2) had worsened when the event
had been present prior to the first dose of INFb-1a. AEs were
assessed at months 3, 6, 12, 18, and 24.
All AEs reported by the patient or observed by study site
personnel were recorded in the patient’s CRF. For patients who
prematurely withdrew from the study AEs were collected within 2
weeks after withdrawal. In addition, for patients who discontinued
because of reasons related to INFb-1a AEs were followed up until
they had resolved.
The AE information recorded included severity - mild,
moderate, severe- and relationship to INFb-1a - unrelated,
unlikely related, likely related, definitely related. Mild: Symptom(s)
barely noticeable to subject or does not make subject uncomfort-
able; does not influence performance or functioning; prescription
drug not ordinarily needed for relief of symptom(s) but may be
given because of personality of subject. Moderate: Symptom(s) of a
sufficient severity to make subject uncomfortable; performance of
daily activity is influenced; subject is able to continue in study;
treatment for symptom(s) may be needed. Severe: Symptom(s)
cause severe discomfort; severity may cause cessation of treatment
with study drug; treatment for symptom(s) may be given and/or
subject hospitalized. For reason of analysis AEs that were assessed
as ‘definitely related’ or ‘likely related’ were termed ‘related AEs’,
and AEs assessed as ‘not related’ or ‘unlikely related’ and those
with missing assessment were termed ‘not related’.
A serious AE (SAE) was defined as: 1) death, 2) life-threatening
event, i.e. an event that places the subject, in the view of the
investigator, at immediate risk of death from the event as it
occurred; 3) event that requires or prolongs hospitalisation; 4)
event that results in persistent or significant disability or incapacity;
5) congenital anomaly or birth defect diagnosed in a child of a
patient; 6) event that necessitates medical or surgical intervention
to prevent one of the outcomes listed above. SAEs that were
unresolved at month 24 or at the time the patient discontinued
INFb-1a treatment were followed up until the event had resolved
or the clinical course had stabilised.
Patients were instructed on management of AEs related to
INFb-1a according to Munschauer and Kinkel, 1997 [26].
Acetaminophen (paracetamol) 625–1000 mg/day Q 4 hours was
advised for influenza-like symptoms, if necessary with changed
time of administration or switch to a NSAID (ibuprofen,
naproxen) with or without acetaminophen (paracetamol). To the
discretion of the neurologist fatigue was to be treated with
amantadine 100 mg twice daily, spasticity with baclophen 10–
20 mg simultaneously with IM INFb-1a injection, then Q 4–
6 hours as needed. AE management was recorded in the CRF.
Data quality assurance and statistics
Data quality was assured by monitoring and data management
procedures. Each site was periodically monitored by a CRO
representative to compare data collected in the CRF with the
investigator’s source document. Source document verification was
20%. Data management and entry were performed by the CRO.
To ensure that entered data accurately reflected those contained in
the CRF, double data entry was performed using TrialBase
TM.
The value entered on first entry was compared to the value
entered on second entry, with any differences flagged for later
resolution. To achieve completeness and consistency of data
automated edits and manual reviews were performed according to
a validation plan prepared in cooperation with the Steering
Committee. Queries were printed, forwarded to the site and
resolved by the investigator. After transfer of data to a statistical
package (SAS, version 8.2 [SAS Institute Inc. Cary NC, USA,
1997]) data correctness was validated according to SOPs. Coded
data and the codes were checked for correctness. No audits were
performed.
The safety analysis set was defined as all subjects who received
at least one dose of INFb-1a and had at least one post-baseline
safety assessment.
AEs were summarized overall, and by severity and relationship
to INFb-1a. The summary tables include incidence estimates for
each overall system organ class and for individual events within
each system organ class. Preferred terms and the COSTART
dictionary version 5 were used to denominate AEs.
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